Skip to main content

NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs

The emergence of psychedelic therapies as a popular investment a few years ago was mostly underscored by investors that rode the cannabis wave seeing a brand-new opportunity with drugs such as psilocybin, LSD, MDMA, DMT, and others to address hard-to-treat mental health diseases, namely depression, addiction, post-traumatic stress disorder and anxiety. As strides are being made on those fronts, a second investment wave is swelling on the horizon that looks to feature expanded indications and bring new therapeutic options to diseases with unmet needs. Psychedelics could redefine standards of care for chronic diseases and reshape psychiatry, including counseling practices, among other things. Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (Profileis leading this next wave of psychedelic drug development beyond mental health into chronic pain and eating disorders as the company advances its clinical programs. With a diverse approach, Tryp is joined by a short list of brand name leaders in psychedelics that includes ATAI Life Sciences N.V. (NASDAQ: ATAI)COMPASS Pathways Plc (NASDAQ: CMPS)Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) and Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), all of which are making significant strides towards validating the legitimate potential of a wide range of psychedelic-based treatment regimens.

To hear the NetworkNewsAudio version, visit https://nnw.fm/HOyFN

To view the full editorial, visit https://nnw.fm/q217O

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and eating disorder indications. The company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://nnw.fm/TRYPF

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.